Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERA Vera Therapeutics, Inc.

Pre-Mkt 05-08 05:05:48 EDT

35.88

-0.71

-1.95%

盘前36.42

+0.54+1.51%

04:22 EDT

High36.90	Low34.47	Vol972.56K
Open36.47	D1 Closing36.60	Amplitude6.64%
Mkt Cap2.57B	Tradable Cap1.80B	Total Shares71.71M
T/O34.56M	T/O Rate1.94%	Tradable Shares50.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VERA","market":"US","secType":"STK","nameCN":"Vera Therapeutics, Inc.","latestPrice":35.88,"timestamp":1778184000000,"preClose":36.595,"halted":0,"volume":972555,"hourTrading":{"tag":"盘前","latestPrice":36.42,"preClose":35.88,"latestTime":"04:22 EDT","volume":1,"amount":36.42,"timestamp":1778228532888,"change":0.54,"changeRate":0.01505,"amplitude":0},"delay":0,"changeRate":-0.019538188277086935,"floatShares":50198200,"shares":71713905,"eps":-4.664443,"marketStatus":"Pre-Mkt","change":-0.715,"latestTime":"05-08 05:05:48 EDT","open":36.47,"high":36.9,"low":34.47,"amount":34558010.7771,"amplitude":0.066403,"askPrice":43.42,"askSize":100,"bidPrice":34.01,"bidSize":56,"shortable":3,"etf":0,"ttmEps":-4.664443,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778247000000},"marketStatusCode":1,"adr":0,"listingDate":1620964800000,"exchange":"NASDAQ","adjPreClose":35.88,"preHourTrading":{"tag":"盘前","latestPrice":36.42,"preClose":35.88,"latestTime":"04:22 EDT","volume":1,"amount":36.42,"timestamp":1778228532888,"change":0.54,"changeRate":0.01505,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":35.88,"preClose":35.88,"latestTime":"18:11 EDT","volume":13402,"amount":480864.9519,"timestamp":1778191874492,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9034024346088254,"impliedVol":0.9027,"impliedVolPercentile":0.628},"requestUrl":"/m/hq/s/VERA/wiki","defaultTab":"wiki","newsList":[{"id":"2633648377","title":"Vera Therapeutics: Buy Rating Reiterated on Strong Atacicept Outlook and Launch Readiness; $73 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2633648377","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633648377?lang=en_us&edition=fundamental","pubTime":"2026-05-08 12:07","pubTimestamp":1778213224,"startTime":"0","endTime":"0","summary":"Analyst Ritu Baral from TD Cowen maintained a Buy rating on Vera Therapeutics and keeping the price target at $73.00. Ritu Baral has given his Buy ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vera-therapeutics-buy-rating-reiterated-on-strong-atacicept-outlook-and-launch-readiness-73-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vera-therapeutics-buy-rating-reiterated-on-strong-atacicept-outlook-and-launch-readiness-73-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633723231","title":"Kodiak Begins Hauling Freight Autonomously With Roehl Transport","url":"https://stock-news.laohu8.com/highlight/detail?id=2633723231","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633723231?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:16","pubTimestamp":1778184960,"startTime":"0","endTime":"0","summary":"Kodiak and Roehl Transport launch autonomous freight service four times per week between Dallas and Houston","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290645/0/en/Kodiak-Begins-Hauling-Freight-Autonomously-With-Roehl-Transport.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4588","AI","BK4585","AIYY","BK4528","BK4551","BK4023","VERA","CHAT","LU2324357040.USD","AGIX","BK4587","BK4139","BK4543","ARTY","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633171223","title":"Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633171223","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633171223?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:08","pubTimestamp":1778184532,"startTime":"0","endTime":"0","summary":"“The team at Vera Therapeutics (VERA) is focused on execution as we advance atacicept toward potential FDA accelerated approval in IgAN,” said Mars...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-reports-q1-eps-1-69-consensus-1-37-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-reports-q1-eps-1-69-consensus-1-37-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633176831","title":"Vera Therapeutics (VERA) Gets a Buy from LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176831","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176831?lang=en_us&edition=fundamental","pubTime":"2026-05-08 03:55","pubTimestamp":1778183725,"startTime":"0","endTime":"0","summary":"In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Vera Therapeutics, with a price target of $90.00. Katkhud...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vera-therapeutics-vera-gets-a-buy-from-lifesci-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vera-therapeutics-vera-gets-a-buy-from-lifesci-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LU2324357040.USD","VERA","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633125810","title":"Vera Therapeutics, Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633125810","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633125810?lang=en_us&edition=fundamental","pubTime":"2026-05-07 22:10","pubTimestamp":1778163023,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, Inc reports results for the quarter ended March 31 - Earnings SummaryVera Therapeutics, Inc VERA.OQ reported a quarterly adjusted loss of $1.69 per share for the quarter ended March","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K1XB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VERA","LU2324357040.USD","BK4139","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633698142","title":"Vera Therapeutics Q1 EPS $(1.69) Misses $(1.34) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633698142","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633698142?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:29","pubTimestamp":1778156984,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.34) by 26.12 percent. This is a 108.64 percent decrease over losses of $(0.81) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52364083/vera-therapeutics-q1-eps-1-69-misses-1-34-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149538","title":"Vera Therapeutics Q1 net loss widens to $121.03 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149538?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:31","pubTimestamp":1778153460,"startTime":"0","endTime":"0","summary":"Vera Therapeutics posted a net loss of $121.03 million, widening from $51.69 million a year earlier; loss per diluted share deepened to $1.69 from $0.81.Operating loss widened to $125.13 million as operating expenses climbed to $125.13 million, led by R&D spending of $86.01 million.Net cash used in operating activities rose to $106.5 million from $54.4 million in the prior-year quarter; cash, cash equivalents, and marketable securities fell to $596.76 million at March 31.FDA granted priority review for atacicept accelerated approval in adult IgA nephropathy, setting a PDUFA date of July 7, 2026; U.S. launch remains planned for mid-2026 pending approval.Initial Phase 2 PIONEER basket-trial results are expected in Q2 2026, with pivotal two-year eGFR data from ORIGIN 3 due in Q1 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL5cCLnW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","BK4112","BK4539","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","LU2324357040.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","VERA","LU0314104364.USD","BK4139","LU2095319765.USD","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149824","title":"BRIEF-Vera Therapeutics Q1 EPS USD -1.69 Vs. IBES Estimate USD -1.33","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149824","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149824?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153448,"startTime":"0","endTime":"0","summary":"BRIEF-Vera Therapeutics Q1 EPS USD -1.69 Vs. IBES Estimate USD -1.33\n\n\nMay 07 (Reuters) - Vera Therapeutics Q1 operating expenses USD 125.132 million.\n\nQ1 operating income USD -125.132 million vs. IBES estimate USD -92.7 million\nQ1 net income USD -121.032 million vs. IBES estimate USD -89.9 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX78E37F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4585","VERA","BK4139","BK4539","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149162","title":"Vera Therapeutics, Inc - U.S. Commercial Launch of Atacicept Expected Mid-2026, Pending Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149162?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX78E37F:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","BK4585","BK4139","BK4539","VERA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633141149","title":"Vera Therapeutics, Inc - $596.8 Mln in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141149?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX78E37F:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4585","VERA","LU2324357040.USD","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633493381","title":"Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633493381","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633493381?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153400,"startTime":"0","endTime":"0","summary":"-- U.S. Food and Drug Administration  granted priority review to. Biologics License Application  for the accelerated approval of. atacicept in adult patients with IgA Nephropathy  with a. Prescription Drug User Fee Act  date of July 7, 2026. -- On track for U.S. commercial launch of atacicept in mid-2026, pending. -- Strong balance sheet expected to be sufficient to fund operations beyond. \"The team at Vera Therapeutics is focused on execution as we advance atacicept toward potential FDA accelerated approval in IgAN,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"During the first quarter, we made meaningful progress across key pre--commercial activities, including in sales, marketing, market access, compliance, and commercial operations, to support a successful U.S. launch, pending regulatory approval. We are excited for atacicept to potentially be the first approved drug targeting both BAFF and APRIL in IgAN patients.\". IgAN in adults, and assigned a PDUFA target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0726765562.USD","LU0868494617.USD","LU1732799900.SGD","LU1430594728.SGD","LU0912757837.SGD","BK4504","BK4585","LU1244550494.USD","IE00BJTD4V19.USD","LU0417517546.SGD","LU1244550577.SGD","LU1069347547.HKD","IE00BFSS8Q28.SGD","TACI","LU0795875169.SGD","LU2347655156.SGD","LU0795875086.SGD","IE00BFSS7M15.SGD","MCD","LU2133065610.SGD","LU1244550221.USD","LU1585245621.USD","LU1732800096.USD","IE00BJJMRX11.SGD","LU0868494708.USD","BK4550","LU2324357040.USD","BK4610","LU0256863811.USD","BK4566","LU0942090050.USD","FSGS","IE00B7KXQ091.USD","LU2279689827.SGD","IE00BJJMRY28.SGD","BK4588","BK4139","LU1035773651.USD","LU1074936037.SGD","IE0004445015.USD","LABU","IE00BJTD4N35.SGD","LU1718418525.SGD","VERA","BK4539","BK4534","LU2347655073.USD","BK4209","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632301899","title":"Vera Therapeutics to present at Bank of America Securities 2026 Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2632301899","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632301899?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:31","pubTimestamp":1777894269,"startTime":"0","endTime":"0","summary":"Vera Therapeutics management to present at Bank of America Securities 2026 Health Care Conference on May 13, 2026 at 4:20 PM PDT.Conference scheduled for May 12-14, 2026 in Las Vegas; management also set for one-on-one investor meetings.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL5mNQPc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","BK4585","SG9999014021.USD","LU2324357040.USD","BK4539","IE00BKPKM429.USD","NDAQ","IE00B64PRP62.GBP","BK4588","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210149790.SGD","VERA","BK4112","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627585792","title":"Vera CEO Marshall Fordyce disposes of Vera Therapeutics shares worth $1,018,054","url":"https://stock-news.laohu8.com/highlight/detail?id=2627585792","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627585792?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:58","pubTimestamp":1776286698,"startTime":"0","endTime":"0","summary":"Vera Therapeutics President and CEO Marshall Fordyce sold 22,951 Class A common shares on April 14, 2026.Sales prices ranged from USD 43.25 to USD 45.67 per share.Fordyce held 235,244 Class A common shares directly following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL1kPYbt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vera CEO Marshall Fordyce disposes of Vera Therapeutics shares worth $1,018,054","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2324357040.USD","BK4139","BK4539","BK4588","VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626148623","title":"BRIEF-Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626148623","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626148623?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:31","pubTimestamp":1775853063,"startTime":"0","endTime":"0","summary":"BRIEF-Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)April 10 (Reuters) - Vera Therapeutics, Inc VERA.O:VERA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nTUA4403KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4588","BK4585","BK4539","VERA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626148699","title":"Vera Therapeutics grants inducement awards to 89 hires, issuing 258,200 options and 131,925 RSUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2626148699","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626148699?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:30","pubTimestamp":1775853014,"startTime":"0","endTime":"0","summary":"Vera Therapeutics granted inducement equity awards to 89 new employees on April 8, 2026 under its 2024 Inducement Plan.Awards included non-qualified stock options covering 258,200 Class A shares.Grants also included RSUs covering 131,925 Class A shares.Stock options carry an exercise price of $40.33 per share.Options vest over four years; RSUs vest over four years starting May 20, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL6VrTKx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","VERA","NDAQ","BK4539","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU2095319765.USD","LU2324357040.USD","BK4112","SG9999014013.SGD","BK4139","SG9999014039.USD","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LU2210150020.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626352130","title":"Vera Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2626352130","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626352130?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:07","pubTimestamp":1775765221,"startTime":"0","endTime":"0","summary":"Vera Therapeutics set annual shareholder meeting for May 21, 2026, to be held via live webcast.Shareholders will vote on election of three Class II directors to serve until 2029 annual meeting.Meeting agenda includes ratification of KPMG as independent registered public accounting firm for fiscal 2026.Advisory vote scheduled on compensation of named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDLbMJMTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","VERA","BK4539","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622870780","title":"Vera Therapeutics grants 56,850 stock options at $40.73; issues 42,403 RSUs under 2024 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2622870780","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622870780?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:05","pubTimestamp":1774641918,"startTime":"0","endTime":"0","summary":"Vera Therapeutics granted non-qualified stock options covering 56,850 Class A shares and RSUs covering 42,403 Class A shares to new Chief Legal Officer Jane Wright-Mitchell.The stock options have an exercise price of USD 40.73 per share and vest over four years.25% of the stock option shares vest on the first anniversary of the vesting start date, with the remainder vesting monthly over 36 months.The RSUs vest over four years, with 25% vesting on each anniversary of May 20, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL545qF2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU0314104364.USD","BK4112","BK4139","SG9999014005.SGD","IE00BN0W2W23.USD","BK4585","LU2210149790.SGD","VERA","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4539","IE00BN0W2V16.EUR","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808757","title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808757","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808757?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:05","pubTimestamp":1774641900,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., March  27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/27/3264085/0/en/Vera-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4585","VERA","LU2324357040.USD","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622078867","title":"Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078867","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078867?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:30","pubTimestamp":1774438229,"startTime":"0","endTime":"0","summary":"Vera Therapeutics appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately.Wright-Mitchell previously served as a fractional general counsel supporting public and private life sciences companies.Her prior roles include General Counsel, Chief Compliance Officer and Corporate Secretary at Vaxcyte, and Chief Legal Officer positions at other pharmaceutical and research companies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL5FDKSy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU0314104364.USD","BK4112","PCVX","BK4139","LU0053671581.USD","SG9999014005.SGD","IE00BN0W2W23.USD","BK4585","LU2210149790.SGD","VERA","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4539","IE00BN0W2V16.EUR","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014021.USD","IE0009354923.USD","LU2210150020.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620342250","title":"Analysts Conflicted on These Healthcare Names: Cochlear (OtherCHEOF), Universal Health (UHS) and Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620342250","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620342250?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750629,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cochlear (CHEOF – Research Report), Universal Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cochlear-othercheof-universal-health-uhs-and-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cochlear-othercheof-universal-health-uhs-and-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0128526141.USD","LU0029874061.USD","UHS","BK4185","HCSG","XBI","BK4137","LABU","VERA","XLV","BK4581","BK4139","LU2324357040.USD","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veratx.com","stockEarnings":[{"period":"1week","weight":0.0076},{"period":"1month","weight":-0.103},{"period":"3month","weight":-0.1752},{"period":"6month","weight":0.4833},{"period":"1year","weight":0.5862},{"period":"ytd","weight":-0.2915}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.1098},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.3037},{"period":"ytd","weight":0.0728}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.057587},{"month":2,"riseRate":0.4,"avgChangeRate":0.015839},{"month":3,"riseRate":0.4,"avgChangeRate":-0.047765},{"month":4,"riseRate":0,"avgChangeRate":-0.103447},{"month":5,"riseRate":0.4,"avgChangeRate":-0.047476},{"month":6,"riseRate":0.4,"avgChangeRate":0.164504},{"month":7,"riseRate":0.8,"avgChangeRate":0.137629},{"month":8,"riseRate":0.6,"avgChangeRate":0.019112},{"month":9,"riseRate":0.6,"avgChangeRate":0.088867},{"month":10,"riseRate":0.2,"avgChangeRate":-0.071412},{"month":11,"riseRate":0.8,"avgChangeRate":0.292871},{"month":12,"riseRate":0.6,"avgChangeRate":0.07812}],"exchange":"NASDAQ","name":"Vera Therapeutics, Inc.","nameEN":"Vera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vera Therapeutics, Inc.,VERA,Vera Therapeutics, Inc.股票,Vera Therapeutics, Inc.股票老虎,Vera Therapeutics, Inc.股票老虎国际,Vera Therapeutics, Inc.行情,Vera Therapeutics, Inc.股票行情,Vera Therapeutics, Inc.股价,Vera Therapeutics, Inc.股市,Vera Therapeutics, Inc.股票价格,Vera Therapeutics, Inc.股票交易,Vera Therapeutics, Inc.股票购买,Vera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction